India’s healthcare sector continues to be a magnet for major institutional capital and public market activity. Maxivision Super Specialty Eye Hospitals, backed by healthcare-focused private equity firm Quadria Capital, has officially appointed ICICI Securities and IIFL Capital to lead its planned 2027 Initial Public Offering (IPO).
Here is the strategic and market breakdown of this upcoming listing:
📊 The Growth Metrics & Market Potential
- The Footprint: Founded in 1996, the Hyderabad-based chain operates over 90 eye-care centres across six Indian states.
- The Market Explosion: Driven by an aging population, rising diabetes rates, and expanding health insurance coverage, India’s eye-care market is projected to skyrocket to $31.2 billion by 2033 (up from $12.8 billion in 2025).
- The Structure: The IPO will feature a dual-mechanism structure, combining newly-issued shares to fund expansion with an offer for sale (OFS) by existing investors.
⚡ India’s Red-Hot Healthcare Consolidation Maxivision’s listing arrives amid unprecedented, multi-billion-dollar momentum in India’s medical infrastructure space:
- Manipal Health Enterprises: Recently filed for a massive IPO aiming to raise up to $1.17 billion.
- Global PE Influx: KKR entered advanced talks last month to acquire a majority stake in a major Indian healthcare operator for at least $1 billion.
💡 The Strategic Takeaway: Specialized healthcare delivery chains are transitioning from local players into massive institutional asset classes. Maxivision’s decision to tap the public markets by 2027 reflects a calculated push to weaponize its capital structure early, ensuring it captures the lion’s share of a rapidly expanding $31B market against heavily backed competitors.